Towards an HIV cure based on targeted killing of infected cells: Different approaches against acute versus chronic infection

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 207-213

  Dey, Barna ^a   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Fc mediated effector functions; genetically modified T cells; HIV cure; Keywords chimeric antigen receptor; recombinant immunotoxins; T cell receptor; targeted cytotoxic therapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; IMMUNOTOXIN; T LYMPHOCYTE RECEPTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD8+ T LYMPHOCYTE; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL CLEARANCE; ANIMAL; COMBINATION DRUG THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE; T LYMPHOCYTE; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MICE; T-LYMPHOCYTES;

EID: 84928538029     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000151     Document Type: Review

References (68)

1. Lewin SR, Deeks SG, Barre-Sinoussi F. Towards a cure for HIV-are we making progress? Lancet 2014; 384:209-211.
2. Siliciano JD, Siliciano RF. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol 2014; 134:12-19.
3. Archin NM, Sung JM, Garrido C, et al. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nature Rev Microbiol 2014; 12:750-764.
4. Ananworanich J, Fauci AS. HIV cure research: A formidable challenge. J Virus Eradiation 2015; 1:1-3.
5. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
6. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5 Delta 32/Delta 32 stem cell transplantation. Blood 2011; 117:2791-2799.
7. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
8. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
9. Rainwater-Lovett K, Luzuriaga K, Persaud D. Very early combination antiretroviral therapy in infants: prospects for cure. CurrOpinHIV AIDS2015; 10:4-11.
10. Berger EA. Targeted cytotoxic therapy: Adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS 2011; 6:80-85.
11. Mitsuyasu R. Curing HIV: lessons from cancer therapy. Curr Opin HIV AIDS 2013; 8:224-229.
12. zur Wiesch JS, van Lunzen J. Hide and seek: can we eradicate HIV by treatment intensification? J Infect Dis 2011; 203:894-897.
13. Wayne AS, FitzGerald DJ, Kreitman RJ, Pastan I. Immunotoxins for leukemia. Blood 2014; 123:2470-2477.
14. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64:15-29.
15. Sgouros G, Goldenberg DM. Radiopharmaceutical therapy in the era of precision medicine. Eur J Cancer 2014; 50:2360-2363.
16. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nature Rev Cancer 2014; 14:559-567.
17. Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 2011; 3:381-394.
18. Bakema JE, van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Topics Microbiol Immunol 2014; 382:373-392.
19. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17:385-392.
20. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010; 6:e1000803.
21. Tsukrov D, Dadachova E. The potential of radioimmunotherapy as a new hope for HIV patients. Expert Rev Clin Immunol 2014; 10:553-555.
22. Mehendale R, Joshi M, Patravale V. Nanomedicines for treatment of viral diseases. Crit Rev Therapeut Drug Carrier Syst 2013; 30:1-49.
23. Winnall WR, Beasley MD, Center RJ, et al. The maturation of antibody technology for the HIV epidemic. Immunol Cell Biol 2014; 92:570-577.
24. Chung AW, Alter G. Dissecting the antibody constant region protective immune parameters in HIV infection. Future Virol 2014; 9:397-414.
25. Guijarro-Munoz I, Compte M, Alvarez-Vallina L, Sanz L. Antibody gene therapy: getting closer to clinical application? Curr Gene Ther 2013; 13:282-290.
26. Balazs AB, West AP Jr. Antibody gene transfer for HIV immunoprophylaxis. Nature Immunol 2013; 14:1-5.
27. Schnepp BC, Johnson PR. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS 2014; 9:250-256.
28. Corrigan-Curay J, Kiem H-P, Baltimore D, et al. T-cell immunotherapy: looking forward. Mol Ther 2014; 22:1564-1574.
29. Lam S, Bollard C. T-cell therapies for HIV. Immunotherapy 2013; 5:407-414.
30. Ananworanich J, Dube K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV AIDS 2015; 10:18-28.
31. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-77.
32. Gilabert-Oriol R, Weng A, von Mallinckrodt B, et al. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: A lethal cocktail with tumor specific efficacy. Curr Pharm Design 2014; 20:6584-6643.
33. Goldstein H, Pettoello-Mantovani M, Bera TK, et al. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-hu mice. J Infect Dis 2000; 181:921-926.
34. Denton PW, Long JM, Wietgrefe SW, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathogens 2014; 10:e1003872.
35. Liu WH, Onda M, Lee B, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A 2012; 109:11782-11787.
36. Mazor R, Eberle JA, Hu XB, et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci U S A 2014; 111:8571-8576.
37. Johnson PR, Schnepp BC, Zhang JC, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-999.
38. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-84.
39. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014; 20:296-300.
40. Fisher K, Voronin Y, Jefferys R. Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects. Vaccine 2014; 32:5540-5545.
41. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
42. Varela-Rohena A, Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Med 2008; 14:1390-1395.
43. Kitchen SG, Levin BR, Bristol G, et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathogens 2012; 8:e1002649.
44. Romeo C, Seed B. Cellular-immunity to HIV activated by CD4 Fused to T-cell or Fc receptor polypeptides. Cell 1991; 64:1037-1046.
45. Roberts MR, Qin L, Zhang DZ, et al. Targeting of human immunodeficiency virus-infected cells by CD8 T lymphocytes armed with universal T-cell receptors. Blood 1994; 84:2878-2889.
46. Yang OO, Tran AC, Kalams SA, et al. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 1997; 94:11478-11483.
47. Bitton N, Verrier F, Debre P, Gorochov G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 1998; 28:4177-4187.
48. Masiero S, Del Vecchio C, Gavioli R, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 2005; 12:299-310.
49. Sahu GK, Sango K, Selliah N, et al. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 2013; 446:268-275.
50. Ni Z, Knorr DA, Bendzick L, et al. Expression of chimeric receptor CD4 zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 2014; 32:1021-1031.
51. MacLean AG, Walker E, Sahu GK, et al. A novel real-time CTL assay to measure designer T-cell function against HIV Env cells. J Med Primatol 2014; 43:341-348.
52. Wu XL, Wang C, O'Dell S, et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 2012; 86:5844-5856.
53. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4 zeta gene-modified autologous CD4 and CD8 T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96:785-793.
54. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96:467-474.
55. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIVspecific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5:788-797.
56. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Translat Med 2012; 4:132ra53.
57. McDermott AB, Koup RA. CD8 T cells in preventing HIV infection and disease. AIDS 2012; 26:1281-1292.
58. Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011; 117:72-82.
59. Maus MV, Haas AR, Beatty GL, et al. T Cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1:26-31.
60. Wonderlich ER, Leonard JA, Collins KL. HIV immune evasion: disruption of antigen presentation by the HIV Nef protein. In Maramorosch K, Shatkin AJ, Murphy FA, editors. Advances in Virus Research, Vol 80. 2011; pp. 103-127.
61. Sacha JB, Chung C, Rakasz EG, et al. Gag-specific CD8() T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178:2746-2754.
62. Brenchley JM, Schacker TW, Ruff LE, et al. CD4 T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
63. Connick E, Mattila T, Folkvord JM, et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol 2007; 178:6975-6983.
64. Hong JJ, Amancha PK, Rogers K, et al. Spatial alterations between CD4 T follicular helper, B, and CD8 T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012; 188:3247-3256.
65. FukazawaY,ParkH,CameronMJ, et al. Lymphnode T cell responses predict the efficacy of live attenuated SIV vaccines. Nature Med 2012; 18:1673-1681.
66. PerreauM, Savoye A-L, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143-156.
67. Connick E, Folkvord JM, Lind KT, et al. Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. J Immunol 2014; 193:5613-5625.
68. Fukazawa Y, Lum R, Okoye AA, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nature Med 2015; 21:132-139.